Reolysin: Interim Phase II data

Interim data from 20 evaluable patients in an ongoing, single-arm, open-label, U.S. Phase II trial showed that daily IV Reolysin on days 1-5 of each 21-day cycle plus paclitaxel and carboplatin produc...